ARUP offers state-of-the-art massively parallel sequencing (MPS), also known as next generation sequencing (NGS), to detect antiviral resistance at levels of sensitivity previously unattainable by Sanger sequencing.

MPS technology enables deeper detection of emerging and existing drug-resistant mutations. Timely detection and identification of drug-resistant viral populations, even at low concentrations, is essential to inform optimal therapy.

Using MPS to detect antiviral resistance genes improves testing by:

  • Providing high sensitivity
  • Interrogating multiple targets simultaneously
  • Handling indel (insertion-deletion variants) calling and interpretation easily
  • Detecting resistance in minority viral populations at as low as 10% of the total viral population, resulting in earlier detection of emerging variants

Test Highlights

Human Immunodeficiency Virus 1 Drug Resistance by Next Generation Sequencing (3003853)

  • All key targets of the reverse transcriptase, protease, and integrase regions are sequenced in a single test.
  • An ARUP-developed, custom bioinformatics pipeline streamlines analysis and provides faster results.
  • Result interpretations are linked to the gold-standard Stanford University HIV Drug Resistance Database, ensuring up-to-date interpretation.
  • Enhanced reports contain a customized chart that lists drug class, drug, evidence of resistance, and the identified variants.
  • Results are reported within 4 to 10 days.

Cytomegalovirus Drug Resistance by Next Generation Sequencing, Ganciclovir, Foscarnet, Cidofovir, Maribavir, and Letermovir (3004615)

  • Multiple genes are sequenced (UL97, UL54, UL27, and UL56) in a single assay to detect more resistance-associated variants.
  • An ARUP-developed, custom bioinformatics pipeline streamlines analysis and provides faster results.
  • Results are reported within 3 to 9 days.

Additional Antiviral Drug Resistance Testing at ARUP

Hepatitis B

  • Hepatitis B Virus Genotype by Sequencing (2001567)
  • Hepatitis B Virus (HBV) by Quantitative NAAT with Reflex to HBV Genotype by Sequencing (3000866)

Hepatitis C

  • Hepatitis C Virus (HCV) NS5A Drug Resistance by Sequencing (2014139)
  • Hepatitis C Virus (HCV) Genotype with Reflex to HCV NS5A Drug Resistance by Sequencing (2014598)

Herpes Simplex Virus

ARUP is one of the only laboratories in the United States that performs a cell culture-based assay to identify herpes simplex virus (HSV) antiviral susceptibility. Cell culture is currently the recommended method to identify antiviral susceptibility, as there are no sequencing databases available for HSV-1 or HSV-2.

  • Antiviral Susceptibility, Herpes Simplex Virus, Foscarnet (2010785)
  • Antiviral Susceptibility, Herpes Simplex Virus, Acyclovir (2010866)

ARUP Consult® Topics

Learn more about HIV testing:

Learn more about CMV testing:

Our Experts

ARUP’s medical directors and consultants are nationally and internationally recognized pathologists, subspecialty-qualified clinicians, and board-certified clinical scientists.

Medical Experts